Pharmaceutical firms look forward to CIIE
Major pharmaceutical companies say they will continue to leverage the China International Import Expo to seek potential local partners and unveil new products essential in the country's health-care blueprint.
Felix Gutsche, president and CEO of Boehringer Ingelheim China, said it sees the event as a good opportunity for government delegations and authorities and relevant sectors to create awareness of innovative products and solutions.
"We host animal and human health businesses under one roof and we regard the CIIE as an excellent platform to show to participants, commercial partners and government authorities the full potential of our innovations," he said.
The German company has seen significant breakthroughs in the products it brought to the CIIE last year and has pledged 451 million euros (US$507.9 million) in investment over the next five years in China.
It has completed drug distribution agreements worth 200 million yuan (US$28.6 million) with a local partner which were signed during the second China International Import Expo.
Last November its diabetes drug was included in the National Reimbursement Drug List.
Another treatment of scoliosis-related interstitial lung diseases also present at the previous CIIE was approved by the National Medical Products Administration earlier this year.
Market approval in China came only six weeks after approval in EU markets thanks to an expedited process by Chinese drug authorities and an early inclusion of China into global clinical studies by the German company.
In previous years there were drug approval backlogs where new drugs would take years to be acknowledged by the local watchdog after they hit the market in developed markets.
This year the company will be present with both a main booth and a second booth at the Public Health and Epidemic Prevention Exhibition Area.
"It's crucial to bring public and private efforts together to develop health care and the CIIE serves as a good platform to bring two sides together," he said.
Dupixent, which was approved in June by the National Medical Products Administration for moderate-to-severe atopic dermatitis in adults, will be the star product for French drug firm Sanofi this year.
"We have been emboldened to see the Chinese economy’s strong resilience and great potential. The upcoming China International Import Expo will become a significant platform for restoring the world’s trade vitality and further promoting international trade,” said Pius Hornstein, head of China, General Medicines and China country lead at Sanofi.
“We will continue to introduce innovative medicines and vaccines to China to benefit patients with the same passion and intention. This year we will bring a more innovative and pioneering look, demonstrating a digital health-care strategy adapted to the needs of Chinese patients.”
Abbott, a first-time participant this year, said it will bring leading solutions in diagnostics, devices, nutrition and pharmaceuticals to the CIIE.
Key exhibits include an integrated testing system for clinical chemistry and immunoassay, implantable heart failure remote-monitoring and sensing system and continuous glucose monitoring technology.
"Participation in the CIIE is an important testament of Abbott’s commitment in the development of Chinese health-care industry and facilitation of the country’s Healthy China agenda,” said Tony Chan, vice president of Abbott’s diagnostics business in China.
In the Public Health and Epidemic Prevention Section, it will bring COVID-19 test kits and technologies, nutrition products and next-generation sensing technology for diabetes management.
The "ID NOW" isothermal system for the qualitative detection of infectious diseases will be present at the section.
GSK's exhibition space of 800 square meters will feature respiratory drugs, vaccines, consumer health-care products.
It will bring the only vaccine of its kind for the prevention of shingles in adults aged 50 and above.
The "Shingrix" vaccine was included on the list of the first batch of 48 “clinically urgently needed innovative medicines" by the National Medical Products Administration and got market approval in China last year.